30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

OrthogenRx Launches TriVisc in the US -

OrthogenRx commenced U.S. launch of TriVisc® sodium hyaluronate for the treatment of knee osteoarthritis pain in a 3-injection regimen. The formulation has received regulatory clearance in 63 countries ex-U.S. and been administered in over 35 million doses worldwide. The company claims it to be the lowest-priced 3-injection hyaluronic acid product derived from a biofermentation process on the U.S. market. (OrthogenRx, Inc., 1/22/19)